Home The Word Brain	My Amedeo FAQ Privacy About
	As of October 2023, Amedeo had 12,263 active subscribers

HIV Infection

Free Subscription Articles published in Antimicrob Agents Chemother Retrieve available abstracts of 54 articles: HTML format

Single Articles

December 2023
1. HAN K, Gevorkyan H, Sadik Shaik J, Crauwels H, et al
   Pharmacokinetics and tolerability of cabotegravir and rilpivirine long-acting intramuscular injections to the vastus lateralis (lateral thigh) muscles of healthy adult participants.
   Antimicrob Agents Chemother. 2023 Dec 1:e0078123. doi: 10.1128/aac.00781.
   PubMed     Abstract available
   
   
   October 2023
2. VAN SCHALKWYK M, Bekker A, Decloedt E, Wang J, et al
   Pharmacokinetics and safety of first-line tuberculosis drugs rifampin, isoniazid, ethambutol, and pyrazinamide during pregnancy and postpartum: results from IMPAACT P1026s.
   Antimicrob Agents Chemother. 2023 Oct 26:e0073723. doi: 10.1128/aac.00737.
   PubMed     Abstract available
   
   
   
3. VAN GULCK E, Pardons M, Nijs E, Verheyen N, et al
   A truncated HIV Tat demonstrates potent and specific latency reversal activity.
   Antimicrob Agents Chemother. 2023 Oct 24:e0041723. doi: 10.1128/aac.00417.
   PubMed     Abstract available
   
   
   
4. KENGO A, Nabisere R, Gausi K, Musaazi J, et al
   Dolutegravir pharmacokinetics in Ugandan patients with TB and HIV receiving standard- versus high-dose rifampicin.
   Antimicrob Agents Chemother. 2023 Oct 18:e0043023. doi: 10.1128/aac.00430.
   PubMed     Abstract available
   
   
   
5. KENGO A, Gausi K, Nabisere R, Musaazi J, et al
   Unexpectedly low drug exposures among Ugandan patients with TB and HIV receiving high-dose rifampicin.
   Antimicrob Agents Chemother. 2023 Oct 18:e0043123. doi: 10.1128/aac.00431.
   PubMed     Abstract available
   
   
   June 2023
6. BONNARD D, Le Rouzic E, Singer MR, Yu Z, et al
   Biological and Structural Analyses of New Potent Allosteric Inhibitors of HIV-1 Integrase.
   Antimicrob Agents Chemother. 2023 Jun 13:e0046223. doi: 10.1128/aac.00462.
   PubMed     Abstract available
   
   
   May 2023
7. HUANG T, Cai J, Wang P, Zhou J, et al
   Ponatinib Represses Latent HIV-1 by Inhibiting AKT-mTOR.
   Antimicrob Agents Chemother. 2023 May 22:e0006723. doi: 10.1128/aac.00067.
   PubMed     Abstract available
   
   
   
8. HAO X, Ni J, Zhao D, Zhang W, et al
   No Meaningful Drug-Drug Interactions Are Associated with the Coadministration of ACC007, Lamivudine, and Tenofovir Disoproxil Fumarate.
   Antimicrob Agents Chemother. 2023 May 1:e0121922. doi: 10.1128/aac.01219.
   PubMed     Abstract available
   
   
   April 2023
9. BERTRAND J, Barrail-Tran A, Fayette L, Savic R, et al
   Pharmacokinetic Model of Tenofovir and Emtricitabine and Their Intracellular Metabolites in Patients in the ANRS 134-COPHAR 3 Trial Using Dose Records.
   Antimicrob Agents Chemother. 2023 Apr 26:e0233918. doi: 10.1128/aac.02339.
   PubMed     Abstract available
   
   
   
10. ELGAMMAL Y, Salama EA, Seleem MN
    Atazanavir Resensitizes Candida auris to Azoles.
    Antimicrob Agents Chemother. 2023 Apr 24:e0163122. doi: 10.1128/aac.01631.
    PubMed     Abstract available
    
    
    
11. XIAO MA, Cleyle J, Yoo S, Forrest M, et al
    The G118R plus R263K Combination of Integrase Mutations Associated with Dolutegravir-Based Treatment Failure Reduces HIV-1 Replicative Capacity and Integration.
    Antimicrob Agents Chemother. 2023 Apr 18:e0138622. doi: 10.1128/aac.01386.
    PubMed     Abstract available
    
    
    
12. WANG C, Huang H, Mallon K, Valera L, et al
    Antiviral Properties of HIV-1 Capsid Inhibitor GSK878.
    Antimicrob Agents Chemother. 2023 Apr 11:e0169422. doi: 10.1128/aac.01694.
    PubMed     Abstract available
    
    
    March 2023
13. MARZINKE MA, Fogel JM, Wang Z, Piwowar-Manning E, et al
    Extended Analysis of HIV Infection in Cisgender Men and Transgender Women Who Have Sex with Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083.
    Antimicrob Agents Chemother. 2023 Mar 30:e0005323. doi: 10.1128/aac.00053.
    PubMed     Abstract available
    
    
    
14. TIETJEN I, Schonhofer C, Sciorillo A, Naidu ME, et al
    The Natural Stilbenoid (-)-Hopeaphenol Inhibits HIV Transcription by Targeting Both PKC and NF-kappaB Signaling and Cyclin-Dependent Kinase 9.
    Antimicrob Agents Chemother. 2023 Mar 28:e0160022. doi: 10.1128/aac.01600.
    PubMed     Abstract available
    
    
    
15. HONG H, Aslam-Mir U, Kajubi R, Wallender E, et al
    Efavirenz-Based Antiretroviral Therapy but Not Pregnancy Increased Unbound Piperaquine Exposure in Women during Malaria Chemoprevention.
    Antimicrob Agents Chemother. 2023 Mar 14:e0142722. doi: 10.1128/aac.01427.
    PubMed     Abstract available
    
    
    February 2023
16. UNDERWOOD M, Horton J, Nangle K, Hopking J, et al
    Correction for Underwood et al., "Integrase Inhibitor Resistance Mechanisms and Structural Characteristics in Antiretroviral Therapy-Experienced, Integrase Inhibitor-Naive Adults with HIV-1 Infection Treated with Dolutegravir plus Two Nucleoside Rever
    Antimicrob Agents Chemother. 2023 Feb 16:e0032622. doi: 10.1128/aac.00326.
    PubMed    
    
    
    
17. CHIREHWA MT, Resendiz-Galvan JE, Court R, De Kock M, et al
    Optimizing Moxifloxacin Dose in MDR-TB Participants with or without Efavirenz Coadministration Using Population Pharmacokinetic Modeling.
    Antimicrob Agents Chemother. 2023 Feb 6:e0142622. doi: 10.1128/aac.01426.
    PubMed     Abstract available
    
    
    January 2023
18. JARRETT RT, van der Heijden Y, Shotwell MS, Chihota V, et al
    High Isoniazid Exposures When Administered with Rifapentine Once Weekly for Latent Tuberculosis in Individuals with Human Immunodeficiency Virus.
    Antimicrob Agents Chemother. 2023 Jan 9:e0129722. doi: 10.1128/aac.01297.
    PubMed     Abstract available
    
    
    
19. BANDA CG, Nkosi D, Allen E, Workman L, et al
    Erratum for Banda et al., "Impact of Dolutegravir-Based Antiretroviral Therapy on Piperaquine Exposure following Dihydroartemisinin-Piperaquine Intermittent Preventive Treatment of Malaria in Pregnant Women Living with HIV".
    Antimicrob Agents Chemother. 2023 Jan 5:e0156222. doi: 10.1128/aac.01562.
    PubMed    
    
    
    November 2022
20. BANDA CG, Nkosi D, Allen E, Workman L, et al
    Impact of Dolutegravir-Based Antiretroviral Therapy on Piperaquine Exposure following Dihydroartemisinin-Piperaquine Intermittent Preventive Treatment of Malaria in Pregnant Women Living with HIV.
    Antimicrob Agents Chemother. 2022 Nov 14:e0058422. doi: 10.1128/aac.00584.
    PubMed     Abstract available
    
    
    
21. BHAVNANI SM, Trang M, Griffith DC, Lomovskaya O, et al
    Pharmacokinetic-Pharmacodynamic Target Attainment Analyses as Support for Meropenem-Vaborbactam Dosing Regimens and Susceptibility Breakpoints.
    Antimicrob Agents Chemother. 2022 Nov 14:e0213021. doi: 10.1128/aac.02130.
    PubMed     Abstract available
    
    
    
22. MATTHEWS RP, Cao Y, Patel M, Weissler VL, et al
    Safety and Pharmacokinetics of Islatravir in Individuals with Severe Renal Insufficiency.
    Antimicrob Agents Chemother. 2022 Nov 8:e0093122. doi: 10.1128/aac.00931.
    PubMed     Abstract available
    
    
    October 2022
23. HO K, Dominguez-Islas C, Szydlo D, Edick S, et al
    MTN-033: a Phase 1 Study Comparing Applicator versus "as Lubricant" Delivery of Rectal Dapivirine Gel.
    Antimicrob Agents Chemother. 2022 Oct 18:e0081622. doi: 10.1128/aac.00816.
    PubMed     Abstract available
    
    
    September 2022
24. LUTERBACH CL, Qiu H, Hanafin PO, Sharma R, et al
    A Systems-Based Analysis of Mono- and Combination Therapy for Carbapenem-Resistant Klebsiella pneumoniae Bloodstream Infections.
    Antimicrob Agents Chemother. 2022 Sep 20:e0059122. doi: 10.1128/aac.00591.
    PubMed     Abstract available
    
    
    
25. SUNDELL J, Bienvenu E, Birgersson S, Abelo A, et al
    Effects of Enzyme Induction and Polymorphism on the Pharmacokinetics of Isoniazid and Rifampin in Tuberculosis/HIV Patients.
    Antimicrob Agents Chemother. 2022 Sep 7:e0227721. doi: 10.1128/aac.02277.
    PubMed     Abstract available
    
    
    August 2022
26. PHAM MM, Podany AT, Mwelase N, Supparatpinyo K, et al
    Population Pharmacokinetic Modeling and Simulation of Rifapentine Supports Concomitant Antiretroviral Therapy with Efavirenz and Non-Weight Based Dosing.
    Antimicrob Agents Chemother. 2022 Aug 9:e0238521. doi: 10.1128/aac.02385.
    PubMed     Abstract available
    
    
    July 2022
27. DEVANATHAN AS, White NR, Desyaterik Y, De la Cruz G, et al
    Quantitative Imaging Analysis of the Spatial Relationship between Antiretrovirals, Reverse Transcriptase Simian-Human Immunodeficiency Virus RNA, and Fibrosis in the Spleens of Nonhuman Primates.
    Antimicrob Agents Chemother. 2022 Jul 20:e0060922. doi: 10.1128/aac.00609.
    PubMed     Abstract available
    
    
    
28. MTSHALI S, Jacobs BA
    A Comparative Analysis of Physiologically Based Pharmacokinetic Models for Human Immunodeficiency Virus and Tuberculosis Infections.
    Antimicrob Agents Chemother. 2022 Jul 19:e0027422. doi: 10.1128/aac.00274.
    PubMed     Abstract available
    
    
    May 2022
29. KAWUMA AN, Wasmann RE, Dooley KE, Boffito M, et al
    Population Pharmacokinetic Model and Alternative Dosing Regimens for Dolutegravir Coadministered with Rifampicin.
    Antimicrob Agents Chemother. 2022 May 23:e0021522. doi: 10.1128/aac.00215.
    PubMed     Abstract available
    
    
    
30. DE NICOLO A, Calcagno A, Motta I, De Vivo E, et al
    The Effect of Rifampicin on Darunavir, Ritonavir, and Dolutegravir Exposure within Peripheral Blood Mononuclear Cells: a Dose Escalation Study.
    Antimicrob Agents Chemother. 2022 May 18:e0013622. doi: 10.1128/aac.00136.
    PubMed     Abstract available
    
    
    
31. DIAMOND TL, Ngo W, Xu M, Goh SL, et al
    Islatravir Has a High Barrier to Resistance and Exhibits a Differentiated Resistance Profile from Approved Nucleoside Reverse Transcriptase Inhibitors (NRTIs).
    Antimicrob Agents Chemother. 2022 May 12:e0013322. doi: 10.1128/aac.00133.
    PubMed     Abstract available
    
    
    
32. VAN DER LAAN LE, Garcia-Prats AJ, Schaaf HS, Chirehwa M, et al
    Pharmacokinetics and Dose Optimization Strategies of Para-Aminosalicylic Acid in Children with Rifampicin-Resistant Tuberculosis.
    Antimicrob Agents Chemother. 2022 May 4:e0226421. doi: 10.1128/aac.02264.
    PubMed     Abstract available
    
    
    
33. GARTLAND M, Cahn P, DeJesus E, Diaz RS, et al
    Week 96 Genotypic and Phenotypic Results of the Fostemsavir Phase 3 BRIGHTE Study in Heavily Treatment-Experienced Adults Living with Multidrug-Resistant HIV-1.
    Antimicrob Agents Chemother. 2022 May 3:e0175121. doi: 10.1128/aac.01751.
    PubMed     Abstract available
    
    
    
34. LAI MT, Feng M, Xu M, Ngo W, et al
    Doravirine and Islatravir Have Complementary Resistance Profiles and Create a Combination with a High Barrier to Resistance.
    Antimicrob Agents Chemother. 2022 May 2:e0222321. doi: 10.1128/aac.02223.
    PubMed     Abstract available
    
    
    April 2022
35. ACOSTA RK, D'Antoni ML, Mulato A, Yant SR, et al
    Forgiveness of INSTI-Containing Regimens at Drug Concentrations Simulating Variable Adherence In Vitro.
    Antimicrob Agents Chemother. 2022 Apr 7:e0203821. doi: 10.1128/aac.02038.
    PubMed     Abstract available
    
    
    March 2022
36. SONG N, Zhou X, Li D, Li X, et al
    A Proteomic Landscape of Candida albicans in the Stepwise Evolution to Fluconazole Resistance.
    Antimicrob Agents Chemother. 2022 Mar 28:e0210521. doi: 10.1128/aac.02105.
    PubMed     Abstract available
    
    
    
37. MOORE K, Thakkar N, Magee M, Sevinsky H, et al
    Pharmacokinetics of Temsavir, the Active Moiety of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir, Coadministered with Cobicistat, Etravirine, Darunavir/Cobicistat, or Darunavir/Ritonavir with or without Etravirine in Healthy Participants.
    Antimicrob Agents Chemother. 2022 Mar 22:e0225121. doi: 10.1128/aac.02251.
    PubMed     Abstract available
    
    
    
38. DIDE-AGOSSOU C, Bauman AA, Ramey ME, Rossmassler K, et al
    Combination of Mycobacterium tuberculosis RS Ratio and CFU Improves the Ability of Murine Efficacy Experiments to Distinguish between Drug Treatments.
    Antimicrob Agents Chemother. 2022 Mar 21:e0231021. doi: 10.1128/aac.02310.
    PubMed     Abstract available
    
    
    
39. WALLACE J, Gonzalez H, Rajan R, Narasipura SD, et al
    Anti-HIV Drugs Cause Mitochondrial Dysfunction in Monocyte-Derived Macrophages.
    Antimicrob Agents Chemother. 2022 Mar 16:e0194121. doi: 10.1128/aac.01941.
    PubMed     Abstract available
    
    
    
40. MWANGI JN, Gilliland WM Jr, White N, Sykes C, et al
    Mass Spectroscopy Imaging of Hair Strands Captures Short-Term and Long-Term Changes in Emtricitabine Adherence.
    Antimicrob Agents Chemother. 2022 Mar 10:e0217621. doi: 10.1128/aac.02176.
    PubMed     Abstract available
    
    
    February 2022
41. HAN K, Wannamaker P, Lu H, Zhu B, et al
    Safety, Tolerability, Pharmacokinetics, and Acceptability of Oral and Long-Acting Cabotegravir in HIV-Negative Chinese Men.
    Antimicrob Agents Chemother. 2022 Feb 7:AAC0205721. doi: 10.1128/AAC.02057.
    PubMed     Abstract available
    
    
    January 2022
42. JEFFREY JL, St Clair M, Wang P, Wang C, et al
    Impact of Integrase Sequences From HIV-1 Subtypes A6/A1 on the In Vitro Potency of Cabotegravir or Rilpivirine.
    Antimicrob Agents Chemother. 2022 Jan 3:AAC0170221. doi: 10.1128/AAC.01702.
    PubMed     Abstract available
    
    
    
43. AMANO M, Yedidi RS, Salcedo-Gomez PM, Hayashi H, et al
    Fluorine-Modifications Contribute to Potent Antiviral Activity against Highly Drug-Resistant HIV-1 and Favorable Blood-Brain Barrier (BBB) Penetration Property of Novel Central Nervous System (CNS)-targeting HIV-1 Protease Inhibitors In Vitro.
    Antimicrob Agents Chemother. 2022 Jan 3:AAC0171521. doi: 10.1128/AAC.01715.
    PubMed     Abstract available
    
    
    December 2021
44. LAI PC, Chen CH, Jeng LB, Yu TM, et al
    Grazoprevir/Elbasvir treatment in liver or kidney transplant recipients with genotype-1b hepatitis C virus infection.
    Antimicrob Agents Chemother. 2021 Dec 13:AAC0200321. doi: 10.1128/AAC.02003.
    PubMed     Abstract available
    
    
    
45. AGUIAR-ALVES F, Le HN, Tran VG, Gras E, et al
    Anti-virulence Bispecific Monoclonal Antibody Mediated Protection Against Pseudomonas aeruginosa Ventilator-Associated Pneumonia in a Rabbit Model.
    Antimicrob Agents Chemother. 2021 Dec 13:AAC0202221. doi: 10.1128/AAC.02022.
    PubMed     Abstract available
    
    
    
46. LOMBAARD J, Ssali F, Thanyawee P, Fourie J, et al
    Long-term safety, tolerability and antiviral activity of rilpivirine in antiretroviral-naive adolescents living with HIV-1, aged 12 to less than 18 years: Week 240 findings of a phase 2, open-label study, PAINT.
    Antimicrob Agents Chemother. 2021 Dec 6:AAC0091621. doi: 10.1128/AAC.00916.
    PubMed     Abstract available
    
    
    November 2021
47. POON R, Basuino L, Satishkumar N, Chatterjee A, et al
    Loss of GdpP function in Staphylococcus aureus leads to beta-lactam tolerance and enhanced evolution of beta-lactam resistance.
    Antimicrob Agents Chemother. 2021 Nov 29:AAC0143121. doi: 10.1128/AAC.01431.
    PubMed     Abstract available
    
    
    
48. DICKER I, Jeffrey JL, Protack T, Lin Z, et al
    GSK3640254 Is a Novel HIV-1 Maturation Inhibitor With an Optimized Virology Profile.
    Antimicrob Agents Chemother. 2021 Nov 15:AAC0187621. doi: 10.1128/AAC.01876.
    PubMed     Abstract available
    
    
    
49. ZHANG CX, Love MS, McNamara CW, Chi V, et al
    Pharmacokinetics and pharmacodynamics of clofazimine for treatment of cryptosporidiosis.
    Antimicrob Agents Chemother. 2021 Nov 8:AAC0156021. doi: 10.1128/AAC.01560.
    PubMed     Abstract available
    
    
    
50. BOYER PL, Rehm CA, Sneller MC, Mican J, et al
    A Combination of Amino Acid Mutations Leads to Resistance to Multiple Nucleoside Analogs in Reverse Transcriptases from HIV-1 Subtypes B and C.
    Antimicrob Agents Chemother. 2021 Nov 1:AAC0150021. doi: 10.1128/AAC.01500.
    PubMed     Abstract available
    
    
    October 2021
51. VAVRO C, Ruel T, Wiznia A, Montanez N, et al
    Emergence of Resistance in HIV-1 Integrase With Dolutegravir Treatment in a Pediatric Population From the IMPAACT P1093 Study.
    Antimicrob Agents Chemother. 2021 Oct 25:AAC0164521. doi: 10.1128/AAC.01645.
    PubMed     Abstract available
    
    
    
52. UNDERWOOD M, Horton J, Nangle K, Hopking J, et al
    Integrase Inhibitor Resistance Mechanisms and Structural Characteristics in Antiretroviral Therapy-Experienced, Integrase Inhibitor-Naive Adults With HIV-1 Infection Treated With Dolutegravir Plus 2 Nucleoside Reverse Transcriptase Inhibitors in the D
    Antimicrob Agents Chemother. 2021 Oct 25:AAC0164321. doi: 10.1128/AAC.01643.
    PubMed     Abstract available
    
    
    
53. DEKKER JG, Klaver B, Berkhout B, Das AT, et al
    Mutations in the HIV-1 3'-polypurine tract can confer dolutegravir resistance.
    Antimicrob Agents Chemother. 2021 Oct 11:AAC0102721. doi: 10.1128/AAC.01027.
    PubMed     Abstract available
    
    
    September 2021
54. ASANTE-APPIAH E, Lai J, Wan H, Yang D, et al
    Impact of HIV-1 Resistance-associated Mutations on Susceptibility to Doravirine: Analysis of Real-world Clinical Isolates.
    Antimicrob Agents Chemother. 2021 Sep 27:AAC0121621. doi: 10.1128/AAC.01216.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO HIV Infection is free of charge.